2D-QSAR, Docking, Molecular dynamics simulations with the MM/GBSA approaches against Grave's disease and PTPN22

2D-QSAR, Docking, Molecular dynamics simulations with the MM/GBSA approaches against Grave's disease and PTPN22

Graves' disease (GD) is an autoimmune condition that frequently causes hyperthyroidism and thyrotoxicosis. Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) isoform 1 (PTPN22), is a promising therapeutic candidate for treating Graves' disease, rheumatoid arthritis, type 1 diab...

Full description

Bibliographic Details
Main Authors:	Emmanuel Israel Edache, Adamu Uzairu, Paul Andrew Mamza, Gideon Adamu Shallangwa
Format:	Article
Language:	English
Published:	Institute for Researches and Community Services Universitas Muhammadiyah Palangkaraya 2023-08-01
Series:	Borneo Journal of Pharmacy
Subjects:	Grave’s disease PTPN22 QSAR Docking Molecular dynamics simulations ADMET
Online Access:	https://journal.umpr.ac.id/index.php/bjop/article/view/4915

Similar Items

Association of PTPN22 polymorphism and its correlation with Graves' disease susceptibility in Polish adult population—A preliminary study
by: Natalia Wawrusiewicz‐Kurylonek, et al.
Published: (2019-06-01)

Computer-aided drug design and in silico pharmacokinetics predictions of some potential antipsychotic agents
by: Sabitu Babatunde Olasupo, et al.
Published: (2021-07-01)

Quantitative Structure-Activity Relationship, Structure-based Design, and ADMET studies of pyrimethamine and cycloguanil analogs inhibitors of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS).
by: Zakari Ya'u Ibrahim, et al.
Published: (2022-12-01)

Virtual screening, pharmacokinetics, and molecular dynamics simulations studies to identify potent approved drugs for Chlamydia trachomatis treatment
by: Emmanuel Israel Edache, et al.
Published: (2021-10-01)

Redoxing PTPN22 activity
by: Magdalena Shumanska, et al.
Published: (2022-05-01)

QSAR and molecular docking studies of 1,3-dioxoisoindoline-4-aminoquinolines as potent antiplasmodium hybrid compounds
by: Aliyu Wappah Mahmud, et al.
Published: (2020-03-01)

Polymorphisms in Protein Tyrosine Phosphatase Non-receptor Type 2 and 22 (PTPN2/22) Are Linked to Hyper-Proliferative T-Cells and Susceptibility to Mycobacteria in Rheumatoid Arthritis
by: Robert C. Sharp, et al.
Published: (2018-01-01)

Association of PTPN22 Haplotypes with Hashimotos Thyroiditis in Population of Novosibirsk
Published: (2009-03-01)

Pharmacokinetic profiling of quinazoline-4(3H)-one analogs as EGFR inhibitors: 3D-QSAR modeling, molecular docking studies and the design of therapeutic agents
by: Sagiru Hamza Abdullahi, PhD, et al.
Published: (2023-10-01)

Redox regulation of PTPN22 affects the severity of T-cell-dependent autoimmune inflammation
by: Jaime James, et al.
Published: (2022-05-01)

Molecular docking and QSAR theoretical model for prediction of phthalazinone derivatives as new class of potent dengue virus inhibitors
by: Samuel Ndaghiya Adawara, et al.
Published: (2020-11-01)

Quantitative Structure-Activity Relationship (QSAR) Studies and Molecular docking Simulation of Norepinephrine Transporter (NET) Inhibitors as Anti-psychotic Therapeutic Agents
by: Sabitu Babatunde OLASUPO, et al.
Published: (2020-02-01)

PTPN22 polymorphisms associated with type 1 diabetes mellitus in ethnic populations of Russian Federation
by: O N Ivanova, et al.
Published: (2013-06-01)

Design, 3D-QSAR, molecular docking, ADMET, molecular dynamics and MM-PBSA simulations for new anti-breast cancer agents
by: Said El Rhabori, et al.
Published: (2024-06-01)

Design of New Derivatives of Dimedone Molecules Using QSAR and Docking Molecular
by: Khaoula Mkhayar, et al.
Published: (2022-11-01)

QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2
by: Abdullahi Bello Umar, et al.
Published: (2020-03-01)

2D QSAR, design, docking study and ADMET of some N-aryl derivatives concerning inhibitory activity against Alzheimer disease
by: Abduljelil Ajala, et al.
Published: (2022-06-01)

Unveiling novel inhibitors of dopamine transporter via in silico drug design, molecular docking, and bioavailability predictions as potential antischizophrenic agents
by: Sabitu Babatunde Olasupo, et al.
Published: (2021-03-01)

A combined 2-D and 3-D QSAR modeling, molecular docking study, design, and pharmacokinetic profiling of some arylimidamide-azole hybrids as superior L. donovani inhibitors
by: Fabian Audu Ugbe, et al.
Published: (2022-06-01)

Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents
by: Sagiru Hamza Abdullahi, et al.
Published: (2022-06-01)

The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease
by: Younes Zaid, et al.
Published: (2018-11-01)

Obstructing Salmonella typhi's virulence in eukaryotic cells through design of its SipB protein antagonists
by: John P. Ameji, M.Sc, et al.
Published: (2023-08-01)

Analysis of <i>PTPN22</i> −1123 G>C, +788 G>A and +1858 C>T Polymorphisms in Patients with Primary Sjögren’s Syndrome
by: Paula Annahi Menchaca-Tapia, et al.
Published: (2023-02-01)

QSAR studies on some C14-urea tetrandrine compounds as potent anti-cancer against Leukemia cell line (K562)
by: Abdullahi Mustapha, et al.
Published: (2018-12-01)

Genetic association of PTPN22 polymorphisms with Type 1 diabetes in Pakistani children
by: Sana Rafaqat, et al.
Published: (2023-12-01)

Modulation of <i>PTPN2/22</i> Function by Spermidine in CRISPR-Cas9-Edited T-Cells Associated with Crohn’s Disease and Rheumatoid Arthritis
by: Ameera M. Shaw, et al.
Published: (2021-08-01)

Combined 3D-QSAR and Molecular Docking Analysis of Thienopyrimidine Derivatives as Staphylococcus aureus Inhibitors
by: Mebarka Ouassaf, et al.
Published: (2021-06-01)

Profiling the antidepressant properties of phenyl piperidine derivatives as inhibitors of serotonin transporter (SERT) via cheminformatics modeling, molecular docking and ADMET predictions.
by: Sabitu Babatunde Olasupo, et al.
Published: (2020-09-01)

QSAR and molecular docking based design of some indolyl-3-ethanone-α-thioethers derivatives as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors
by: Zakari Ya’u Ibrahim, et al.
Published: (2020-06-01)

Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein–Human ACE2 Receptor Interface
by: Wojciech Płonka, et al.
Published: (2020-10-01)

Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling
by: Sagiru Hamza Abdullahi, et al.
Published: (2023-08-01)

A novel QSAR model for designing, evaluating,and predicting the anti-MES activity of new 1H-pyrazole-5-carboxylic acid derivatives
by: Adedirin Oluwaseye, et al.
Published: (2017-07-01)

The Tyrosine Phosphatase Activity of PTPN22 Is Involved in T Cell Development via the Regulation of TCR Expression
by: Bin Bai, et al.
Published: (2023-09-01)

The relationship between rs2488457 Polymorphism of PTPN22 Gene and Recurrent Pregnancy Loss (RPL)
by: Fatemeh Khanbarari, et al.
Published: (2017-11-01)

Quantitative structure-activity relationship, molecular docking, drug-likeness, and pharmacokinetic studies of some non-small cell lung cancer therapeutic agents
by: Muhammad Tukur Ibrahim, et al.
Published: (2020-12-01)

Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET properties
by: Abdullahi Bello Umar, et al.
Published: (2020-10-01)

Docking Simulations and Virtual Screening to find Novel Ligands for T3S in Yersinia pseudotuberculosis YPIII, A drug target for type III secretion (T3S) in the Gram-negative pathogen Yersinia pseudotuberculosis
by: Emmanuel Edache, et al.
Published: (2021-05-01)

The association between PTPN22 C1858T gene polymorphism and type 1 diabetes mellitus: an Indonesian study
by: Nur Rochmah, et al.
Published: (2023-12-01)

Crispr/Cas Mediated Deletion of PTPN22 in Jurkat T Cells Enhances TCR Signaling and Production of IL-2
by: Cara Bray, et al.
Published: (2018-11-01)

QSAR, simulation techniques, and ADMET/pharmacokinetics assessment of a set of compounds that target MAO-B as anti-Alzheimer agent
by: Abduljelil Ajala, et al.
Published: (2023-01-01)